Press Releases

August 8, 2018

BOSTON , Aug. 08, 2018 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq:ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and Chief Executive Officer, is scheduled to present at the Wedbush PacGrow

August 7, 2018

A4250 Phase 3 trial in PFIC underway A4250 granted rare pediatric disease designation, eligible to apply for priority review voucher Management to host conference call and webcast today at 8:30 a.m. EDT BOSTON , Aug. 07, 2018 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc.

July 25, 2018

--- Pediatrician with extensive orphan drug development expertise --- --- Experience with multiple Phase 3 programs and FDA submissions --- BOSTON , July 25, 2018 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq:ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile

June 25, 2018

BOSTON , June 25, 2018 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq:ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that it has been added to the Russell 2000 ® Index as part of the annual reconstitution of the Russell stock

May 29, 2018

BOSTON , May 29, 2018 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq:ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that Ron Cooper , President and Chief Executive Officer, is scheduled to present at the Jefferies 2018 Global